Qnasl (Beclomethasone Dipropionate) Patent Expiration, LOE Window & CMS Spending
Qnasl (Beclomethasone Dipropionate) by Teva Pharmaceuticals: FDA Orange Book LOE 2031-10-21, 2 AB generics, $7.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N202813 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-10-21 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $7.1M |
| 2024 Medicare Part D Spend | $4.5M |
| 2024 Medicaid Spend | $2.6M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 21.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.